Iovance Biotherapeutics, Inc.
IOVA · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $2 | $2 | $1 | $3 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $2 | $2 | $1 | $3 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 13,699% | – | – | – |
| Gross Profit | $0 | -$0 | $0 | $0 |
| % Margin | 24.4% | -804.5% | – | – |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -214.3% | -35,948.9% | – | – |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -226.8% | -37,345.4% | – | – |
| EPS Diluted | -1.28 | -1.89 | -2.49 | -2.23 |
| % Growth | 32.3% | 24.1% | -11.7% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |